21:16 , Nov 9, 2018 |  BC Week In Review  |  Company News

Cue, LG in biologics deal

Cue Biopharma Inc. (NASDAQ:CUE) granted LG Chem Life Sciences exclusive development and commercialization rights in certain Asian-Pacific countries, including Japan, China and Korea, and Australia to CUE-101 and Cue's Immuno-STAT biologics that target T cells...
22:53 , Jan 5, 2018 |  BC Week In Review  |  Company News

Inovio, ApolloBio amend VGX-3100 deal

Inovio Pharmaceuticals Inc. (NASDAQ:INO) and ApolloBio Corp. (NEEQ:430187) amended a deal granting ApolloBio exclusive rights to develop and commercialize VGX-3100 in Taiwan and China, including Hong Kong and Macau, to treat or prevent pre-cancerous infections...
21:30 , Sep 29, 2017 |  BC Week In Review  |  Financial News

Cue Biopharma proposes $40M IPO

On Sept. 21, cancer play Cue Biopharma Inc. (Cambridge, Mass.) proposed to raise up to $40 million in an IPO on NASDAQ underwritten by MDB Capital Group and Feltl. Cue emerged from stealth mode in...
21:19 , Sep 22, 2017 |  BC Extra  |  Financial News

Cue Biopharma proposes $40M IPO

Cancer play Cue Biopharma Inc. (Cambridge, Mass.) proposed to raise up to $40 million in an IPO on NASDAQ underwritten by MDB Capital Group and Feltl. Cue emerged from stealth mode in January with a...
23:03 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other...
16:08 , Jun 7, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy An immortalized human adult erythroid cell line could be used to generate RBCs for transfusion. The cell line was generated from adult human CD34 + bone marrow cells transduced with a tetracycline-inducible...
23:33 , Feb 10, 2017 |  BioCentury  |  Emerging Company Profile

Improving the original immunotherapy

Recombinant IL-2 was one of the first immunotherapies marketed for cancer but is not widely used due to severe off-target toxicities. Cue Biopharma Inc. is developing preclinical programs that deliver IL-2 only to T cells...
23:50 , Jan 27, 2017 |  BioCentury  |  Finance

Activation on cue

Cue Biopharma Inc. emerged from stealth mode last week with a financing led by MDB Capital Group that will enable the cancer play to reach the clinic with its lead therapy, which could trigger a...
01:11 , Jan 25, 2017 |  BC Extra  |  Financial News

Cue Biopharma launches, reveals funding

Cancer immunotherapy company Cue Biopharma Inc. (Cambridge, Mass.) launched Tuesday and announced the close of a $16.4 million round led by MDB Capital Group. The company is developing modular biologics that join a T cell...
02:27 , Nov 5, 2016 |  BioCentury  |  Finance

Turbocharging Turnstone

Turnstone Biologics Inc. ’s $41.4 million series B round provides enough runway to ramp up the company’s clinical program and run four Phase I/II trials over the next three years. OrbiMed Advisors led last week’s...